<DOC>
	<DOCNO>NCT00016601</DOCNO>
	<brief_summary>The purpose study look level depo-medroxyprogesterone acetate ( DMPA Depo-Provera ) blood see affect certain anti-HIV drug ( nelfinavir [ NFV ] , efavirenz [ EFV ] , indinavir [ IDV ] combination ritonavir [ RTV ] , nevirapine [ NVP ] ) . This study also look level anti-HIV drug see affected DMPA . DMPA hormonal birth control method give injection . It know take DMPA together anti-HIV drug change amount DMPA and/or amount anti-HIV drug blood . If high level DMPA occur , side effect may increase . If low level anti-HIV drug occur , drug may become less effective HIV . This study look level anti-HIV drug DMPA blood medication use together .</brief_summary>
	<brief_title>Depo-Medroxyprogesterone Acetate ( DMPA , Depo-Provera ) Use With Certain Anti-HIV Drugs HIV-Infected Women</brief_title>
	<detailed_description>DMPA , injectable depot formulation medroxyprogesterone ( MPA ) , commonly use form `` progestin-only '' contraception . Information limit specific P450 isozymes metabolize MPA ; however , appear CYP3A4 1 pathway hepatic clearance . Drugs known inhibitor CYP3A4 pathway ( protease inhibitor [ PIs ] ) may lead elevated concentration MPA . Secondly , MPA give DMPA injection show induce activity CYP3A4 25 percent . It possible action may result enhanced clearance substrate CYP3A4 , include PIs nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) , turn may result reduce drug exposure possible ARV failure . This study design address lack information potential interaction PIs NNRTIs DMPA . Patients enrol 1 5 arm base current ARV regimen : Arm A ( control group ) : No current ARVs receiving nucleoside reverse transcriptase inhibitor ( NRTIs ) . Arm B : NFV ( 1250 mg bid 750 mg tid ) combination NRTIs . Arm C : EFV ( 600 mg qd ) combination NRTIs . Arm D : IDV ( 800 mg bid ) RTV ( 100 mg bid 200 mg bid ) combination NRTIs . Arm E : NVP ( 200 mg bid ) combination NRTIs . Acceptable NRTIs fix combination medication include : zidovudine ( ZDV ) , lamivudine , didanosine , stavudine ( d4T ) , zalcitabine , abacavir ; concurrent therapy use ZDV d4T allow . ARV therapy provide study . One dose DMPA provide patient entry ( Day 0 ) optional dose DMPA available final visit ( Week 12 ) interest continue DMPA outside protocol experience adverse event first DMPA injection . Patients Arms B , C , D , E intensive pharmacokinetic sample do entry Week 4 measure ARV level . All patient blood test Weeks 2 , 4 , 6 , 8 , 10 , 12 measure level DMPA progesterone . In addition , test monitor HIV-1 RNA level , CD4 CD8 count , hematology , blood chemistry , liver function perform periodically .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have plasma HIV1 RNA ( level HIV blood ) 10,000 copies/ml within 30 day study entry . Had last menstrual period ( LMP ) less 35 day study entry . Have serum folliclestimulating hormone 40 MIU/ml LMP occur 35 day study entry . Have antiHIV drug least 30 day study entry , take antiHIV drug . If take antiHIV drug , patient must tell antiHIV drug within 3 month study entry chosen take future . Intend continue antiHIV drug , take , least 3 month study entry . Have CD4 cell count 200 cells/mm3 take antiHIV drug , CD4 cell count 350 cells/mm3 take antiHIV drug , within 30 day study entry . Have menopause ( change life ) normal reproductive system . Have infection AIDSrelated disease require drug within 14 day study entry . Are 13 year age old . Are female . Have negative pregnancy test within 30 day study entry . Agree avoid become pregnant entire study . If sexually active , agree use least 1 barrier method birth control ( male female condom without spermicide [ cream gel kill sperm ] diaphragm cervical cap spermicide ) receive DMPA study . Have consent parent guardian 18 year age . Weigh least 40 kg ( 88 lb ) within certain range ideal body weight . Exclusion Criteria Patients eligible study : Have take antiHIV drug within 30 day study entry chosen take . Are take 1 NRTI . Are take antiHIV drug list treatment group , include tenofovir , amprenavir , lopinavir/ritonavir , take tenofovir , amprenavir , lopinavir/ritonavir within 30 day study entry . Have take ZDV d4T together within 30 day study entry . Are able take antiHIV drug properly study , opinion investigator . Are allergic DMPA , MPA , ingredient DMPA . Have receive DMPA within 180 day study entry . Have receive hormone ( Provera , oral contraceptive , hormonal replacement therapy , anabolic drug [ e.g. , nandrolone decanoate , megestrol acetate ] ) within 30 day study entry . Are take follow : amiodarone , astemizole , bepridil , buspirone , carbamazepine , cimetidine , cisapride , clarithromycin , cyclosporine , dihydroergotamine , diltiazem , ergotamine , erythromycin , flecainide , glucocorticoid , grapefruit juice , St. John 's wort , itraconazole , ketoconazole , lovastatin , midazolam , nefazodone , phenobarbital , phenytoin , pimozide , pioglitazone , propafenone , propofol , quinidine , rifabutin , rifampin , rosiglitazone , simvastatin , tacrolimus , terfenadine , ticlopidine , triazolam , verapamil . Have take follow drug within 30 day study entry : amiodarone , astemizole , bepridil , buspirone , carbamazepine , cisapride , clarithromycin , cyclosporine , dihydroergotamine , ergotamine , erythromycin , flecainide , glucocorticoid , St. John 's wort , itraconazole , ketoconazole , lovastatin , midazolam , nefazodone , phenobarbital , phenytoin , pimozide , pioglitazone , propafenone , propofol , quinidine , rifabutin , rifampin , rosiglitazone , simvastatin , tacrolimus , terfenadine , ticlopidine , triazolam . Have start , stop , change dos , within 30 day study entry , certain drug include : benzodiazepine , except midazolam triazolam ; bupropion ; calcium channel blocker , except diltiazem verapamil ; fluconazole ; lipidlowering drug except pravastatin ( i.e. , atorvastatin , cerivastatin , fluvastatin , lovastatin simvastatin ) ; isoniazid ; mexiletine ; zaleplon ; zolpidem . The patient , however , remain stable dos drug study . Are receive methadone maintenance treatment le 60 day study entry . Are breastfeed . Have baby within 30 day study entry . Have uterus ovary remove . Abuse drug alcohol . Can stop drinking alcohol 1 day test entry Week 4 . Have change smoking habit within 6 week study entry . Patients may either stop start smoke 6 week study entry . Have cancer reproductive system , vaginal bleed unknown cause , thyroid problem , liver tumor , serious eye problem time study entry . Are take investigational drug without approval protocol chair .</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Delayed-Action Preparations</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Medroxyprogesterone 17-Acetate</keyword>
	<keyword>efavirenz</keyword>
</DOC>